BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 30 October 1996
This patent is assigned to Yale University and is exclusively licensed to VION.
This compound, L-2', 3'-didehydro-dideoxy-5-fluorocytidine, also known as B-L-Fd4C, is one of a series of antiviral compounds licensed from Yale University by VION. B-L-Fd4C is a nucleoside analog. The compound shows potent inhibition against the replication of the Hepatitis B virus (HBV) in combination with very low toxicity to the host cells (i.e., animal or human tissue).
At the Vector Securities Conference last month in Cambridge, England, VION's vice president, research and development, Dr. Terrence W. Doyle said that the compound has 12-20 times the potency of 3TC against HBV and HIV, and is capable of synergizing the activity of D4T and AZT against HIV.
VION is a biopharmaceutical company dedicated to discovering, developing and commercializing oncology and antiviral products. The Company's anticancer agent Promycin(TM) (porfiromycin) is currently in Phase III clinical trials.
--30--amp/ny*
CONTACT: VION Pharmaceuticals Inc. Thomas E. Klein Chief Financial Officer 203/498-4210 or Media Relations Harrison, Star, Wiener & Beitler PR Reva Jaffe Wayman 212/822-6637 or Investor Relations Burns McClellan Ruth Markowitz 212/505-1919
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961030
BW961029
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .